4th May 2017 12:05
Notice of AGM and publication of Annual Report
4 May 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report and financial statements for the year ended 31 December 2016 ("Annual Report and Accounts"), including the Notice of Annual General Meeting ("AGM"), is available for download on the Company's website www.silence-therapeutics.com. The Annual Report and Accounts will be posted to shareholders on or before 9 May 2017.
The AGM will be held at 10am on Friday 2 June 2017, at the offices of Silence Therapeutics Plc, 72 Hammersmith Road, London, United Kingdom W14 8TH.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Henry Fitzgerald-O'Connor/Emma Gabriel
| Tel: +44 (0)20 7523 8350 |
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Related Shares:
SLN.L